The largest phase 3 trial of a treatment for IgA nephropathy (IgAN) showed positive results for sibeprenlimab, Otsuka announced in a news release. The company’s investigation antibody halved proteinuria, a key marker of kidney damage, compared to a placebo after nine months of treatment.

“We are confident about the potential of sibeprenlimab and are grateful to the patients who are helping to further the science by participating in these important trials,” said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development and Commercialization.

Sibeprenlimab targets APRIL, a cytokine in the tumor necrosis family that the news release says plays a key role in the development of IgAN. Proteinuria control is an important independent predictor

See Full Page